Department of Oncology, Aarhus University Hospital/Aarhus University, Entrance C, Level 1, C118, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Department of Clinical Medicine and Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Breast Cancer Res Treat. 2022 Feb;191(3):611-621. doi: 10.1007/s10549-021-06462-7. Epub 2021 Nov 25.
Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS).
Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B).
We enrolled 850 eligible patients. During the 5 years of follow-up, 90 invasive breast cancer recurrences were diagnosed over 3807 person-years. In multivariable analyses, high baseline levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR = 2.30 [95% CI 1.13-4.68]). However, high baseline levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR = 1.23 [95% CI 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR = 1.34 [95% CI 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR = 1.12 [95% CI 0.61-2.05]).
High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes.
在参加马尔默饮食与癌症研究（MDCS）的患者中，研究循环脂质与乳腺癌结局之间的关系。
在 MDCS 女性队列入组时采集的血液中测量循环脂质水平（N=17035）。我们确定了所有在 1991 年至 2014 年间诊断出患有侵袭性乳腺癌的 MDCS 参与者。随访时间从乳腺癌诊断开始，持续到乳腺癌复发、死亡、移民或随访 5 年的第一个事件。我们估计了 5 年的复发发生率，并使用 Cox 回归模型计算了根据载脂蛋白 A-1（Apo A-1）和载脂蛋白 B（Apo B）特定队列三分位数的粗和调整后的风险比（HR）及其 95%置信区间（95%CI）的乳腺癌复发以及全因死亡率。
我们纳入了 850 名符合条件的患者。在 5 年的随访期间，在 3807 人年中诊断出 90 例侵袭性乳腺癌复发。在多变量分析中，Apo B 的基线水平较高与复发率增加相关（三分位 3 与 1 相比，HR=2.30[95%CI 1.13-4.68]）。然而，Apo B 的基线水平与全因死亡率无关（三分位 3 与 1 相比，HR=1.23[95%CI 0.68-2.25]）。我们没有观察到 Apo A-1 水平与复发（三分位 3 与 1 相比，HR=1.34[95%CI 0.70-2.58]）或全因死亡率（三分位 3 与 1 相比，HR=1.12[95%CI 0.61-2.05]）之间的关联。
高预诊断 Apo B 水平与乳腺癌患者的复发风险增加相关。循环 Apo A-1 与乳腺癌结局无关。
